Abstract:Abstract Background The CDST (Clinical Decision Support Tool) was developed to predict response to vedolizumab in Crohn’s disease to identify a subgroup of super responders (SR). We aimed to 1) confirm that prediction of CDST is specific to vedolizumab versus ustekinumab, 2) to determine the weight of each item included in CDST to predict the response to vedolizumab in order to explain its specificity. Methods From the VENUS cohort, all patients with CD treated with ustekinumab (UST) or vedolizumab (VDZ) after exposure to at least one anti-TNF were included consecutively in two referral centers. The primary endpoint was corticosteroid-free clinical remission (CFREM) defined by a CDAI < 150 at W 54. CFREM was also assessed at W 14. All analyzes were adjusted using propensity scores based on patient and CD characteristics, concomitant treatments and disease severity. To understand the weight of the items, CDST was calculated only with the clinical items, by adding the CRP (CDST 4 items) and full CDST (CDST 4 items + 0.4 x albuminemia). Patients were considered as super responders (SR) if 3-items CDST > 3, a 4-items CDST > 3 or a complete CDST > 19. Results Overall, 312 patients (UST = 224 and VDZ = 88) were included. After adjustment, UST was more effective than VDZ in achieving CFREM at W54 (50.6% vs 40.6%, p=0.047) with no difference at W14 (56.1% vs 56.7%, p=0.99). The 3-item CDST was not predictive of CFREM with VDZ at W14 (52% vs 56%, p = ns) or W54 (41% vs 41%, p = ns) in non-SR or SR patients, respectively, while it predicted response to UST at W54 (44% vs 60%, p < 0.01). The 4-item CDST was associated with CFREM with VDZ at W14 (46% vs 67%) and W54 (38% vs 54%) and with UST at W14 (51% vs 73%) and W54 (44% vs 70 %) (p<0.05 for all comparisons). The rate of CFREM was not different between UST and VDZ in non-SR or SR (at W14 andW54). Full CDST was predictive of CFREM at W14 in pts treated with VDZ (50% vs 71%, p<0.05) but not at W54 (41% vs 50%, p = ns). CDST did not predict UST efficacy. In SR patients according to full CDST, VDZ seemed more effective to achieve CFREM at W54 than UST (50% vs 33%), contrary to non-SR (46% vs 36% in favor of UST). The same trend was observed for CFREM at W14: 66% vs 71% in SR and 55% vs 50% in non-SR with UST and VDZ, respectively. In VDZ group, albumin level at baseline was associated with CFREM at W14 (33.7 ± 6.0 vs 39.4 ± 5.3; p = 0.033), contrary to the UST group (37.7 ± 5.5 vs 37.4 ± 9.3; p = 0.54). Conclusion CDST is predictive of CFREM with vedolizumab but not with ustekinumab. The specificity of CDST to vedolizumab is mainly driven by albuminemia. The impact of albumin level on vedolizumab is not fully explained by drug clearance and suggests an increased need for albumin to transport vedolizumab to its target.

P1026 Clinical decision support tool for vedolizumab could not predict outcome in ulcerative colitis patients – a retrospective real-life single-centre cohort study

P773 Clinical decision support tool for vedolizumab is useful in predicting endoscopic remission in Crohn's disease – a retrospective real-life single-centre cohort study

P1028 Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

P922 A multicenter retrospective real-world study to determine the optimal cases of vedolizumab-treated UC patients

P578 CDST (Clinical Decision Support Tool) is predictive of steroid-free clinical remission in patients with Crohn's disease treated with vedolizumab in a specific manner which is mainly driven by the serum level of albumin

P640 Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study

P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline

P527 Factors associated with choice of treatment regimen after the induction period in patients with Ulcerative Colitis treated with vedolizumab

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.

DOP06 Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis

OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis

The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study

Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

Predictors of the efficacy of vedolizumab in patients with ulcerative colitis

P627 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion study

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment

P776 A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-world Clinical Practice in China: Interim Analysis of Safety results

P990 A Multi-center, Single-arm, Prospective, Observational, Real-world Study in China to Evaluate Effectiveness of Vedolizumab in the Treatment of Inflammatory Bowel Diseases: First Interim Analysis of Patient-reported Outcomes